Review Article
Roles of Lymphocyte Kv1.3-Channels in the Pathogenesis of Renal Diseases and Novel Therapeutic Implications of Targeting the Channels
Table 2
Summary of Kv1.3-channel inhibition and its functional outcomes.
| | Authors | Cells | Kv1.3-channel inhibitors used | Functional outcomes of Kv1.3-channel inhibition |
| | Villalonga et al. [76] | Raw 264.7 macrophages
Jurkit T-lymphocytes | Margatoxin
Charybdotoxin | Immunomodulatory effect | | Kalman et al. [77] | L929 cell line stably
expressing Kv1.3 | ShK-Dap22 | Immunomodulatory effect | | Schmitz et al. [78] | L929 cell line stably
expressing Kv1.3 | PAP-1 | Immunomodulatory effect | | Kazama et al. [38] | Murine thymocytes | Margatoxin | Membrane stabilization
Immunomodulatory effect | | Leanza et al. [80] | Cancer cell lines
(MCF-7, DLD-1 etc.) | PAP-1
Psora-4 | Cellular proliferation
Apoptosis regulation | | Hamilton et al. [79] | Skeletal muscle cell
lines (C2C12, L6) | Margatoxin
PAP-1
Psora-4 | Increased glucose uptake
Increased AMPK activity |
|
|
ShK: Stichodactyla helianthus toxin; PAP-1: 5-(4-phenylbutoxy) psoralen.
AMPK: 5′ adenosine monophosphate-activated protein kinase.
|
